Pharmaceutical innovations in wound healing and tissueregeneration

Wound healing is a complex, multistage biological process involving haemostasis, inflammation, proliferation, and remodeling. Chronic wounds, such as diabetic foot ulcers, pressure sores, and venous leg ulcers, often stall in this cascade due to persistent cellular dysfunction, resulting in prolonged morbidity and significant healthcare burdens. Conventional treatments largely provide symptomatic relief without addressing the underlying biological impairments. This mini-review critically evaluates recent pharmaceutical innovations designed to target specific molecular mechanisms that enhance wound repair and tissue regeneration. A focused analysis of preclinical and clinical studies highlights promising strategies including growth factors (e.g., PDGF, VEGF) that stimulate fibroblast activation and angiogenesis; bioengineered skin substitutes and stem cell-based scaffolds that support re-epithelialization and extracellular matrix remodeling; and nanocarrier systems that enable targeted, controlled drug delivery with reduced systemic toxicity. Additionally, gene and RNA-based therapies show potential in modulating wound microenvironments by restoring disrupted signaling pathways, while smart dressings incorporate responsive biomaterials to allow precise, environment-triggered drug release. These emerging approaches collectively offer targeted, effective solutions for managing complex wounds. However, their successful clinical translation necessitates interdisciplinary collaboration, regulatory oversight, and efforts to improve affordability, accessibility, and long-term safety across diverse healthcare settings.